

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



| Section 1. Identifying Inform | mation | |
|--|--|--|
| 1. Given Name (First Name) Daniel | 2. Surname (Last Name) Weiner | 3. Date 27-December-2018 |
| 4. Are you the corresponding author? | ☐ Yes ✓ No | Corresponding Author's Name Nitender Goyal |
| 5. Manuscript Title Kidney Transplantation 1 in Lupus Nep | ohritis: Can We Do Even Bet | ter? |
| 6. Manuscript Identifying Number (if you k M18-3721 | now it) | |
| | | |
| Section 2. The Work Under C | Consideration for Public | cation |
| | g but not limited to grants, da | a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation, |
| Section 3. Relevant financial | activities outside the s | submitted work. |
| of compensation) with entities as desc | ribed in the instructions. Use port relationships that we | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication . |
| Section 4. Intellectual Prope | rty Patents & Copyri | ghts |
| Do you have any patents, whether plan | nned, pending or issued, br | roadly relevant to the work? Yes V No |



| Section 5. | Relationships not covered above |
|------------|---------------------------------|
| | Relationships not covered above |

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

No other relationships/conditions/circumstances that present a potential conflict of interest

the following relationships exist with industry and foundations, none of which are related to the current editorial discussing lupus nephritis or kidney transplantation. These are included for full transparency:

- 1. My institution receives support for my efforts as the Medical Director of Clinical Research for Dialysis Clinic, Inc., a not-for-profit national provider of dialysis services. In this role, I run DCI-related research projects and advise the director of research on the research enterprise. I have represented DCI on Advisory Boards for Keryx Biopharmaceuticals and Relypsa Inc (with funds paid to DCI).
- 2. Participated in a Diabetic Kidney Disease Advisory Board for Janssen Biopharmaceuticals
- 3. Participated in a Dialysis Advisory Board for Akebia Therapeutics
- 4. Receive honoraria as chair of the American Society of Nephrology Quality Committee and from the National Kidney Foundation/Elsevier for editorial positions on the American Journal of Kidney Diseases and Kidney Medicine
- 5. Tufts Medical Center received funds via contract from the University of Utah for work on the SPRINT trial and its extension, SPRINT ASK. University of Utah was funded by a contract from the NIH.
- 6. My institution received support for my efforts consulting for Tricida for study design for the VALOR trial of advanced CKD. In the future, I will receive an honorarium from a 3rd party contract research institution for work as Adjudications Committee Co-Chair for the VALOR Trial.
- 7. Support paid to my institution for work as a site PI for diabetic kidney disease trials for Janssen and AstraZeneca.
- 8. Support paid to my institution for work as a site PI for a renal denervation trial for Boston Scientific.
- 9. Support paid to DCI and to my institution for work as a site PI for dialysis trials by Baxter and Ardelyx.

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Weiner reports and the following relationships exist with industry and foundations, none of which are related to the current editorial discussing lupus nephritis or kidney transplantation. These are included for full transparency:

- 1. My institution receives support for my efforts as the Medical Director of Clinical Research for Dialysis Clinic, Inc., a not-for-profit national provider of dialysis services. In this role, I run DCI-related research projects and advise the director of research on the research enterprise. I have represented DCI on Advisory Boards for Keryx Biopharmaceuticals and Relypsa Inc (with funds paid to DCI).
- 2. Participated in a Diabetic Kidney Disease Advisory Board for Janssen Biopharmaceuticals
- 3. Participated in a Dialysis Advisory Board for Akebia Therapeutics
- 4. Receive honoraria as chair of the American Society of Nephrology Quality Committee and from the National Kidney Foundation/Elsevier for editorial positions on the American Journal of Kidney Diseases and Kidney Medicine
- 5. Tufts Medical Center received funds via contract from the University of Utah for work on the SPRINT trial and its extension, SPRINT ASK. University of Utah was funded by a contract from the NIH.
- 6. My institution received support for my efforts consulting for Tricida for study design for the VALOR trial of advanced CKD. In the future, I will receive an honorarium from a 3rd party contract research institution for work as Adjudications Committee Co-Chair for the VALOR Trial.
- 7. Support paid to my institution for work as a site PI for diabetic kidney disease trials for Janssen and AstraZeneca.
- 8. Support paid to my institution for work as a site PI for a renal denervation trial for Boston Scientific.
- 9. Support paid to DCI and to my institution for work as a site PI for dialysis trials by Baxter and Ardelyx.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Levey 1



| Section 1. Ident | tifying Information | | |
|---|--|-------------------|---|
| 1. Given Name (First Name Andrew | e) 2. Surna Levey | me (Last Name) | 3. Date 27-December-2018 |
| 4. Are you the correspond | ing author? Yes | √ No | Corresponding Author's Name Nitender Goyal |
| 5. Manuscript Title "Kidney Transplantation | in Lupus Nephritis: Can \ | We Do Even Bet | ter?" |
| 6. Manuscript Identifying I | Number (if you know it) | | |
| | | | |
| Section 2. The V | Vork Under Considera | tion for Publ | ication |
| | d work (including but not lii | | n a third party (government, commercial, private foundation, etc.) for lata monitoring board, study design, manuscript preparation, |
| Section 3. Relev | ant financial activitie | s outside the | submitted work. |
| Place a check in the app of compensation) with e | ropriate boxes in the tab entities as described in th . You should report relati | e to indicate whe | hether you have financial relationships (regardless of amount Use one line for each entity; add as many lines as you need by ere present during the 36 months prior to publication . |
| Section 4. Intell | ectual Property Pat | ents & Copyri | ights |
| Do you have any patent | s, whether planned, pend | ling or issued, b | oroadly relevant to the work? Yes Vo |

Levey 2



| Section 5. Relationships not covered above |
|--|
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |
| Yes, the following relationships/conditions/circumstances are present (explain below): |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement |
| Disclosure Statement |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. |
| Dr. Levey has nothing to disclose. |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Levey 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Goyal 1



| Section 1. | Identifying Inform | ation | | | |
|---|---|--|--|---|--|
| 1. Given Name (Fi | rst Name) | 2. Surname (Last Name) 3. Date Goyal 28-December-2018 | | | |
| 4. Are you the cor | re you the corresponding author? Yes No | | | | |
| 5. Manuscript Title "Kidney Transpla | e antation in Lupus Nephi | ritis: Can We Do | Even Better?" | | |
| 6. Manuscript Ider M18-3721 | ntifying Number (if you kn | ow it) | | | |
| | ı | | | | |
| Section 2. | The Work Under Co | onsideration | for Publication | | |
| any aspect of the s statistical analysis, | ubmitted work (including | but not limited t | | | mmercial, private foundation, etc.) for esign, manuscript preparation, |
| Section 3. | Relevant financial | activities out | side the submitted | d work | |
| Place a check in to of compensation clicking the "Add | the appropriate boxes i n) with entities as descri | n the table to ir bed in the instr port relationship | ndicate whether you h uctions. Use one line | nave financial rela for each entity; a | ationships (regardless of amount add as many lines as you need by nonths prior to publication. |
| Section 4. | Intellectual Proper | ty Patents | & Copyrights | | |
| Do you have any | patents, whether plani | ned, pending o | r issued, broadly relev | /ant to the work? | ? ☐ Yes ✓ No |

Goyal 2



| Section 5. | |
|------------------|---|
| Section 5. | Relationships not covered above |
| | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work? |
| Yes, the follo | wing relationships/conditions/circumstances are present (explain below): |
| ✓ No other rela | tionships/conditions/circumstances that present a potential conflict of interest |
| | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships. |
| Section 6. | Disclosure Statement |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box |
| Dr. Goyal has no | thing to disclose. |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Goyal 3